| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Center for Health Studies, Group Health Cooperative of Puget Sound; and the Departments of Epidemiology and Biostatistics, School of Public Health and Community Medicine; and the Department of Medicine, School of Medicine, University of Washington, Seattle, Washington.
Address reprint requests to: Delia Scholes, PhD Center for Health Studies Group Health Cooperative of Puget Sound 1730 Minor Avenue, Suite 1600 Seattle, WA 98101 E-mail: scholes.d{at}ghc.org
Objective: To evaluate the possible effects of depot medroxyprogesterone acetate injectable contraception on bone mineral density in reproductive-age women.
Methods: We conducted a population-based cross-sectional comparison of bone mineral density levels in women using depot medroxyprogesterone acetate contraception and in women of similar age not using this method. The study recruited 457 nonpregnant women aged 18–39 years who were enrollees of a Washington state health maintenance organization. One hundred eighty-three women were receiving injections and 274 were not. Bone mineral density at several anatomic sites (spine, femoral neck, greater trochanter, and whole body) was measured using dual-energy x-ray absorptiometry. Data on other factors potentially related to bone density were collected through questionnaire and examination.
Results: Overall, age-adjusted mean bone density levels were lower for users of this method than for nonusers at all anatomic sites: The mean difference was 2.5% for the spine (P = .03) and 2.2% for the femoral neck (P = .12). Exposure to depot medroxyprogesterone acetate continued to be significantly (P < .01) associated with decreased bone density at the femoral neck, spine, and trochanter after multivariate adjustment for other risk factors related to bone density. Age-specific comparisons indicated that the major differences in bone density between users and nonusers occurred in the youngest age group (women 18–21 years); the mean femoral neck bone density was 10.5% lower (P < .01) for the exposed women, and differences were consistent (P < .01) across all anatomic sites. We also noted a significant dose-response relation between longer use of depot medroxyprogesterone acetate and decreased bone density levels in this age group (P < .01 for all sites).
Conclusion: These results provide evidence that contraception with depot medroxyprogesterone acetate, particularly long-term use, may adversely affect bone mineral density levels in young women aged 18–21 years. The implications for future bone health need further study.
This article has been cited by other articles:
|
|
 |
|
  J. S. Walsh, R. Eastell, and N. F. A. Peel Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1317 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Committee on Adolescence Contraception and Adolescents Pediatrics, November 1, 2007; 120(5): 1135 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tincani, M. Nuzzo, A. Lojacono, M. Cattalini, and A. Meini Review: Contraception in adolescents with systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 600 - 605. [Abstract] [PDF]
|
|
|
|
 |
|
 The ESHRE Capri Workshop Group Noncontraceptive health benefits of combined oral contraception Hum. Reprod. Update, September 1, 2005; 11(5): 513 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Scholes, A. Z. LaCroix, L. E. Ichikawa, W. E. Barlow, and S. M. Ott Change in Bone Mineral Density Among Adolescent Women Using and Discontinuing Depot Medroxyprogesterone Acetate Contraception Arch Pediatr Adolesc Med, February 1, 2005; 159(2): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Taveira-DaSilva, M. P. Stylianou, C. J. Hedin, O. Hathaway, and J. Moss Bone Mineral Density in Lymphangioleiomyomatosis Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Berenson, C. R. Breitkopf, J. J. Grady, V. I. Rickert, and A. Thomas Effects of Hormonal Contraception on Bone Mineral Density After 24 Months of Use Obstet. Gynecol., May 1, 2004; 103(5): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Cundy, R. Ames, A. Horne, J. Clearwater, H. Roberts, G. Gamble, and I. R. Reid A Randomized Controlled Trial of Estrogen Replacement Therapy in Long-Term Users of Depot Medroxyprogesterone Acetate J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 78 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Curtis, C. E. Chrisman, and H. B. Peterson Contraception for Women in Selected Circumstances Obstet. Gynecol., June 1, 2002; 99(6): 1100 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Berenson, C. M. Radecki, J. J. Grady, V. I. Rickert, and A. Thomas A Prospective, Controlled Study of the Effects of Hormonal Contraception on Bone Mineral Density Obstet. Gynecol., October 1, 2001; 98(4): 576 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Ott, D. Scholes, A. Z. LaCroix, L. E. Ichikawa, C. K. Yoshida, and W. E. Barlow Effects of Contraceptive Use on Bone Biochemical Markers in Young Women J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 179 - 185. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Cromer and Z. Harel Adolescents: At Increased Risk for Osteoporosis? Clinical Pediatrics, October 1, 2000; 39(10): 565 - 574. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Beerthuizen, A. van Beek, R. Massai, L. Makarainen, J. i.'t Hout, and H. C. Bennink Bone mineral density during long-term use of the progestagen contraceptive implant Implanon(R) compared to a non-hormonal method of contraception Hum. Reprod., January 1, 2000; 15(1): 118 - 122. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
